# EDGAR Filing Document

**Accession Number:** 0000896262
**File Stem:** 0000896262-23-000014
**Filing Date:** 2023-2
**Character Count:** 102746
**Document Hash:** a685cc9c4a7c692fc9962be741fc010b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000896262-23-000014.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0000896262-23-000014

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 41

**CONFORMED PERIOD OF REPORT**: 20230210

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMEDISYS INC
- **CENTRAL INDEX KEY:** 0000896262
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOME HEALTH CARE SERVICES [8082]
- **IRS NUMBER:** 113131700
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-24260
- **FILM NUMBER:** 23635441

**BUSINESS ADDRESS:**
- **STREET 1:** 3854 AMERICAN WAY
- **STREET 2:** SUITE A
- **CITY:** BATON ROUGE
- **STATE:** LA
- **ZIP:** 70816
- **BUSINESS PHONE:** 2252922031

**MAIL ADDRESS:**
- **STREET 1:** 3854 AMERICAN WAY
- **STREET 2:** SUITE A
- **CITY:** BATON ROUGE
- **STATE:** LA
- **ZIP:** 70816

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANALYTICAL NURSING MANAGEMENT CORP
- **DATE OF NAME CHANGE:** 19940819

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** M&N CAPITAL CORP
- **DATE OF NAME CHANGE:** 19930125

?xml version="1.0" ? amed-20230210

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 10, 2023** 

**Commission File Number: 0-24260**![amed-20230210_g1.jpg](amed-20230210_g1.jpg)

**AMEDISYS, INC.** 

**(Exact Name of Registrant as specified in its Charter)** 

---

| | |
|:---|:---|
| **Delaware** | **11-3131700** |
| **(State or other jurisdiction of <br>incorporation or organization)** | **(I.R.S. Employer <br>Identification No.)** |

---

**3854 American Way, Suite A, Baton Rouge, LA 70816** 

**(Address of principal executive offices, including zip code)**

**(225) 292-2031 or (800) 467-2662**

**(Registrant's telephone number, including area code)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.001 per share** | **AMED** | **The NASDAQ Global Select Market** |

---

---

| | |
|:---|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| Emerging growth company  | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻  | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻  |

---

------

**SECTION 1 — REGISTRANT'S BUSINESS AND OPERATIONS**

**ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT**

On February 10, 2023, Amedisys, Inc. ("we," "us," "our" or the "Company") and two of its wholly-owned subsidiaries, Associated Home Care, L.L.C. and Amedisys Personal Care, LLC, entered into an Equity Purchase Agreement (the "Purchase Agreement"), pursuant to which the Company will sell its personal care line of business, excluding the Florida operations (the "PCL Business"), to HouseWorks Holdings, LLC (the "Buyer") for total consideration of $50 million, subject to certain adjustments as provided in the Purchase Agreement.

The Purchase Agreement contains customary representations, warranties and covenants as well as indemnification provisions.

The transaction is subject to customary closing conditions and regulatory requirements. The parties expect to close the transaction during the second quarter of 2023.

The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, a copy of which will be filed with the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2023. The Purchase Agreement contains representations and warranties by each of the parties. These representations and warranties were made solely for the benefit of the parties to the Purchase Agreement and (i) may have been used for purposes of allocating risk between the respective parties rather than establishing matters as facts, (ii) may have been qualified in the Purchase Agreement by confidential disclosure schedules that were delivered to the other party in connection with the signing of the Purchase Agreement, which disclosure schedules may contain information that modifies, qualifies and creates exceptions to the representations, warranties and covenants set forth in the Purchase Agreement, (iii) may be subject to a contractual standard of materiality applicable to the parties that differs from what a stockholder may view as material and (iv) may have been made only as of the date of the Purchase Agreement or as of another date or dates as may be specified in the Purchase Agreement, and information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in the Company's public disclosures, if at all. Accordingly, stockholders should not rely upon representations and warranties or any descriptions thereof as characterizations of the actual state of facts or condition of the Company, the Buyer or their respective subsidiaries and affiliates.

**SECTION 2 — FINANCIAL INFORMATION**

**ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION**

On February 15, 2023, the Company issued a press release (the "Press Release") announcing its financial results for the fourth quarter and year ended December 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information presented in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless we specifically state that the information is to be considered "filed" under the Exchange Act or specifically incorporate it by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act.

**SECTION 7 – REGULATION FD**

**ITEM 7.01. REGULATION FD DISCLOSURE**

Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.

In addition, a copy of the supplemental slides which will be discussed during the Company's earnings call at 11:00 a.m. ET on Thursday, February 16, 2023 is attached to this report as Exhibit 99.2 and incorporated herein by reference.

On February 15, 2023, the Company issued a press release announcing the divestiture of the PCL Business. A copy of the press release is furnished as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.

Also on February 15, 2023, the Company issued a press release announcing that the Company's subsidiary, Contessa Health Management, LLC, has entered into an agreement with BlueCross BlueShield of Tennessee to provide members in Middle Tennessee with palliative care in the comfort of their home. A copy of the press release is furnished as Exhibit 99.4 to this Current Report on Form 8-K and is incorporated herein by reference.

------

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1, 99.2, 99.3 and 99.4 hereto) is being "furnished" and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1, 99.2, 99.3 and 99.4 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

**SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS**

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| 99.1 | <u>[Press release dated February](a20223112_991exhibit.htm)[15](a20223112_991exhibit.htm)[, 202](a20223112_991exhibit.htm)[3](a20223112_991exhibit.htm)[announcing the Company's financial results for the fourth quarter and year ended December 31, 202](a20223112_991exhibit.htm)[2](a20223112_991exhibit.htm)[(furnished only)](a20223112_991exhibit.htm)</u> |
| 99.2 | <u>[Supplemental slides provided in connection with the fourth quarter 2022 earnings call of the Company (furnished only)](amed4q22ecsupplementalsl.htm)</u> |
| 99.3 | <u>[Press release dated February 15, 2023 announcing the Company's divestiture of its personal care line of business](a20223112_993exhibit.htm)</u> |
| 99.4 | <u>[Press release dated February 15, 2023 announcing the Company's partnership agreement with BlueCross BlueShield of Tennessee](a20223112_994exhibit.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.

(Registrant)

By:&nbsp;&nbsp;&nbsp;&nbsp;<u>/s/ Scott G. Ginn</u> 

&nbsp;&nbsp;&nbsp;&nbsp;Scott G. Ginn

&nbsp;&nbsp;&nbsp;&nbsp;Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer

&nbsp;&nbsp;&nbsp;&nbsp;(Principal Financial Officer)

DATE: February 15, 2023

## Exhibit 99.1

**Exhibit 99.1**

![draftof8k050418image11.gif](draftof8k050418image11.gif)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**AMEDISYS REPORTS FOURTH QUARTER AND YEAR-END 2022 FINANCIAL RESULTS, ISSUES 2023 GUIDANCE, ANNOUNCES SALE OF ITS PERSONAL CARE LINE OF BUSINESS AND SIGNS INNOVATIVE PALLIATIVE CARE AT HOME PARTNERSHIP WITH BLUECROSS BLUESHIELD OF TENNESSEE**

BATON ROUGE, Louisiana (February 15, 2023) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2022.

<u>Three-Month Periods Ended December 31, 2022 and 2021</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Net service revenue increased $2.7 million to $562.0 million compared to $559.3 million in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Net income attributable to Amedisys, Inc. of $31.7 million compared to $34.0 million in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Net income attributable to Amedisys, Inc. per diluted share of $0.97 compared to $1.04 in 2021.

<u>Adjusted Quarterly Results\*</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $59.9 million compared to $64.8 million in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net service revenue of $562.0 million compared to $559.3 million in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income attributable to Amedisys, Inc. of $38.0 million compared to $38.8 million in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.16 compared to $1.18 in 2021.

<u>Years Ended December 31, 2022 and 2021</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Net service revenue increased $9.1 million to $2,223.2 million compared to $2,214.1 million in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Net income attributable to Amedisys, Inc. of $118.6 million compared to $209.1 million in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Net income attributable to Amedisys, Inc. per diluted share of $3.63 compared to $6.34 in 2021.

<u>Adjusted Year End Results\*</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $262.1 million compared to $299.6 million in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net service revenue of $2,232.5 million compared to $2,207.6 million in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income attributable to Amedisys, Inc. of $163.4 million compared to $196.1 million in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income attributable to Amedisys, Inc. per diluted share of $5.01 compared to $5.95 in 2021.

\* See pages 2 and 14-16 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.

<u>2023 Guidance</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net service revenue is anticipated to be in the range of $2.244 billion to $2.274 billion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA is anticipated to be in the range of $230 million to $240 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted diluted earnings per share is anticipated to be in the range of $4.13 to $4.36 based on an estimated 32.9 million shares outstanding.

This guidance excludes the effects of any future acquisitions and potential share repurchases, if any are made.

------

<u>Personal Care Divestiture</u>

On February 10, 2023, we signed a definitive agreement to sell our personal care line of business (excluding the Florida operations). The divestment is expected to close during the second quarter of 2023.

<u>BlueCross BlueShield of Tennessee Palliative Care Partnership</u>

We also announced a new agreement between Contessa Health Management, LLC, an Amedisys subsidiary, and BlueCross BlueShield of Tennessee to provide members in Middle Tennessee with palliative care in the comfort of their home.

Paul B. Kusserow, Chairman and Chief Executive Officer stated, "I am very pleased with the way we closed out 2022 and thankful for the efforts of our nearly 20,000 associates who helped to deliver a strong quarter of performance. 2022 was a tumultuous year, but we are building momentum and have started 2023 off on the right foot. Our focus on people, growth, clinical optimization and Contessa will pay dividends as we progress throughout 2023, and our commitment to our patients and the highest quality care will help to further differentiate Amedisys. I am also thrilled to announce that we have signed an innovative partnership with BlueCross BlueShield of Tennessee to provide palliative care at home. This partnership is the first true example of the power of a combined Amedisys and Contessa platform, and we are excited to be able to expand our care continuum to best serve BlueCross BlueShield's membership. Finally, we announced that we will be divesting our personal care line of business. We are committed to building personal care networks and look forward to the continued engagement with our network partners. 2023 will be an exciting year for Amedisys, and we look forward to consistency in our performance, continued innovation across all our lines of business and expanding our reach so that more patients can receive care where they want it most, their homes."

*We urge caution in considering the current trends and 2023 guidance disclosed in this press release. The home health, hospice, personal care and high acuity care industries are highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission ("SEC") including our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC's internet website, <u>http://www.sec.gov</u>, and our internet website, <u>http://www.amedisys.com</u>.* 

**Earnings Call and Webcast Information**

Amedisys will host a conference call on Thursday, February 16, 2023, at 11:00 a.m. ET to discuss its fourth quarter and year-end results. To participate on the conference call, please call before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through March 16, 2022 by dialing (877) 660-6853 (Toll-Free) or (201) 612-7415 (Toll) and entering conference ID #13735891.

A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: <u>http://investors.amedisys.com.</u>

**Non-GAAP Financial Measures**

This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. ("GAAP") to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net service revenue, defined as net service revenue excluding certain items; (3) adjusted other operating income, defined as other operating income excluding certain items; (4) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. excluding certain items; and (5) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company's financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

**Additional information**

Amedisys, Inc. (the "Company") is a leading healthcare at home company delivering personalized home health, hospice, personal care and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care, recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease, or hospice care at the end of life. Over 3,000 hospitals and 102,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a

------

publicly held company. With approximately 20,000 employees in 532 care centers within 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 465,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com.

We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled "Investors" on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

**Forward-Looking Statements**

When included in this press release, words like "believes," "belief," "expects," "strategy," "plans," "anticipates," "intends," "projects," "estimates," "may," "might," "could," "would," "should" and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors or payment methodologies; changes in the case mix of our patients; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

**Contact:&nbsp;&nbsp;&nbsp;&nbsp;<u>Investor Contact:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Media Contact:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Amedisys, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amedisys, Inc.**

**Nick Muscato&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kendra Kimmons**

**Chief Strategy Officer &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vice President, Marketing & Communications**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(615) 928-5452&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (225) 299-3720**

<u>IR@amedisys.com</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>kendra.kimmons@amedisys.com</u>

------

**AMEDISYS, INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Amounts in thousands, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month <br>Periods Ended December 31,** | **For the Three-Month <br>Periods Ended December 31,** | **For the Years Ended<br>December 31,** | **For the Years Ended<br>December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| | **(Unaudited)** | **(Unaudited)** | | |
| Net service revenue | $562064 | $559317 | $2223199 | $2214112 |
| Other operating income |  |  |  | 13300 |
| Cost of service, excluding depreciation and amortization | 317167 | 317168 | 1260425 | 1233356 |
| General and administrative expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Salaries and benefits | 132003 | 125185 | 508791 | 474718 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-cash compensation | 570 | 5949 | 16560 | 23809 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 60856 | 53718 | 228707 | 212713 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5230 | 9138 | 24935 | 30901 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment charge |  |  | 3009 |  |
| Operating expenses | 515826 | 511158 | 2042427 | 1975497 |
| Operating income | 46238 | 48159 | 180772 | 251915 |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 70 |  | 178 | 49 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (5781) | (2791) | (22228) | (9525) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity in earnings (loss) from equity method investments | 397 | 1017 | (45) | 4949 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on equity method investments |  | 6 |  | 31098 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Miscellaneous, net | 412 | 492 | 1567 | 1745 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other (expense) income, net | (4902) | (1276) | (20528) | 28316 |
| Income before income taxes | 41336 | 46883 | 160244 | 280231 |
| Income tax expense | (9790) | (12873) | (42545) | (70065) |
| Net income | 31546 | 34010 | 117699 | 210166 |
| Net loss (income) attributable to noncontrolling interests | 171 | 37 | 910 | (1094) |
| Net income attributable to Amedisys, Inc. | $31717 | $34047 | $118609 | $209072 |
| Basic earnings per common share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to Amedisys, Inc. common stockholders | $0.98 | $1.04 | $3.65 | $6.41 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted average shares outstanding | 32511 | 32594 | 32517 | 32642 |
| Diluted earnings per common share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to Amedisys, Inc. common stockholders | $0.97 | $1.04 | $3.63 | $6.34 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted average shares outstanding | 32602 | 32823 | 32653 | 32972 |

---

------

**AMEDISYS, INC. AND SUBSIDIARIES**

**CONSOLIDATED BALANCE SHEETS**

**(Amounts in thousands, except share data)**

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2022** | **2021** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $40540 | $42694 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | 13593 | 3075 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patient accounts receivable | 296785 | 274961 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 11628 | 10356 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 26415 | 25598 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 388961 | 356684 |
| Property and equipment, net of accumulated depreciation of $101,364 and $96,937 | 16026 | 18435 |
| Operating lease right of use assets | 102856 | 101257 |
| Goodwill | 1287399 | 1196090 |
| Intangible assets, net of accumulated amortization of $14,604 and $19,900 | 101167 | 111190 |
| Deferred income tax assets |  | 289 |
| Other assets | 79836 | 73023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1976245 | $1856968 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $43735 | $38217 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payroll and employee benefits | 125387 | 141001 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 137390 | 150836 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term obligations | 15496 | 12995 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | 33521 | 31233 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 355529 | 374282 |
| Long-term obligations, less current portion | 419420 | 432075 |
| Operating lease liabilities, less current portion | 69504 | 69309 |
| Deferred income tax liabilities | 20411 |  |
| Other long-term obligations | 4808 | 4979 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 869672 | 880645 |
| Equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value, 60,000,000 shares authorized; 37,891,186 and 37,674,868 shares issued; and 32,518,278 and 32,509,969 shares outstanding | 38 | 38 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 755063 | 728118 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treasury stock at cost, 5,372,908 and 5,164,899 shares of common stock | (461200) | (435868) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 757672 | 639063 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Amedisys, Inc. stockholders' equity | 1051573 | 931351 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interests | 55000 | 44972 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 1106573 | 976323 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $1976245 | $1856968 |

---

------

**AMEDISYS, INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING**

**(Amounts in thousands, except statistical information)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month <br>Periods Ended December 31,** | **For the Three-Month <br>Periods Ended December 31,** | **For the Years Ended <br>December 31,** | **For the Years Ended <br>December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| | **(Unaudited)** | **(Unaudited)** | | |
| **Cash Flows from Operating Activities:** |  |  |  |  |
| Net income | $31546 | $34010 | $117699 | $210166 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5230 | 9138 | 24935 | 30901 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash compensation | 570 | 5949 | 16560 | 23809 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization and impairment of operating lease right of use assets | 11247 | 10183 | 46029 | 40364 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on disposal of property and equipment | 12 | (60) | 519 | (124) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on equity method investments |  | (6) |  | (31098) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 4346 | 9853 | 23377 | 44582 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity in (earnings) loss from equity method investments | (397) | (1017) | 45 | (4949) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred debt issuance costs/debt discount | 248 | 248 | 991 | 917 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Return on equity method investments | 1365 | 1075 | 5163 | 5343 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment charge |  |  | 3009 |  |
| Changes in operating assets and liabilities, net of impact of acquisitions: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patient accounts receivable | 4036 | (392) | (14230) | (18030) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 16404 | (5983) | (3525) | (12202) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 155 | (79) | 438 | (1017) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (992) | (3161) | 4894 | (4353) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | (12592) | (17552) | (39382) | (26915) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term obligations | (9065) | (27011) | (8822) | (28796) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (10311) | (9273) | (41175) | (36645) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease right of use assets | (919) | (756) | (3242) | (3060) |
| Net cash provided by operating activities | 40883 | 5166 | 133283 | 188893 |
| **Cash Flows from Investing Activities:** |  |  |  |  |
| Proceeds from the sale of deferred compensation plan assets | 163 | 9 | 252 | 135 |
| Proceeds from the sale of property and equipment |  | 4 | 66 | 144 |
| Purchases of property and equipment | (1827) | (1115) | (6165) | (6302) |
| Investments in technology assets | (202) | (272) | (1050) | (419) |
| Investment in equity method investee |  | (200) | (637) | (200) |
| Purchase of cost method investment |  | (5000) | (15000) | (5000) |
| Acquisitions of businesses, net of cash acquired |  | (5093) | (71952) | (269965) |
| Net cash used in investing activities | (1866) | (11667) | (94486) | (281607) |
| **Cash Flows from Financing Activities:** |  |  |  |  |
| Proceeds from issuance of stock upon exercise of stock options | 1226 | 348 | 2304 | 2054 |
| Proceeds from issuance of stock to employee stock purchase plan | 991 | 946 | 3848 | 3968 |
| Shares withheld to pay taxes on non-cash compensation | (32) | (204) | (7981) | (16898) |
| Noncontrolling interest contributions | 1401 | 250 | 3501 | 250 |
| Noncontrolling interest distributions | (136) | (494) | (1561) | (1747) |
| Proceeds from sale of noncontrolling interest | 1876 |  | 5817 |  |
| Proceeds from borrowings under term loan |  |  |  | 290312 |
| Proceeds from borrowings under revolving line of credit | 50500 |  | 534500 | 500700 |
| Repayments of borrowings under revolving line of credit | (69000) |  | (534500) | (551700) |
| Principal payments of long-term obligations | (3170) | (3250) | (13296) | (9143) |
| Debt issuance costs |  |  |  | (2792) |
| Provider relief fund advance |  | (58535) |  | (60000) |
| Purchase of company stock |  | (14999) | (17351) | (99878) |
| Payment of accrued contingent consideration |  |  | (5714) |  |
| Net cash (used in) provided by financing activities | (16344) | (75938) | (30433) | 55126 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 22673 | (82439) | 8364 | (37588) |
| Cash, cash equivalents and restricted cash at beginning of period | 31460 | 128208 | 45769 | 83357 |
| Cash, cash equivalents and restricted cash at end of period | $54133 | $45769 | $54133 | $45769 |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month <br>Periods Ended December 31,** | **For the Three-Month <br>Periods Ended December 31,** | **For the Years Ended <br>December 31,** | **For the Years Ended <br>December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| | **(Unaudited)** | **(Unaudited)** | | |
| **Supplemental Disclosures of Cash Flow Information:** |  |  |  |  |
| Cash paid for interest | $5786 | $1812 | $14939 | $5291 |
| Cash paid for Infinity ZPIC interest | $1211 | $— | $12755 | $— |
| Cash paid for income taxes, net of refunds received | $431 | $8615 | $24013 | $34097 |
| **Supplemental Disclosures of Non-Cash Activity:** |  |  |  |  |
| Accrued contingent consideration | $— | $— | $19195 | $— |
| Noncontrolling interest contribution | $— | $— | $8900 | $— |
| Days revenue outstanding (1) | 46.1 | 43.2 | 46.1 | 43.2 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Our calculation of days revenue outstanding at December 31, 2022 and 2021 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended December 31, 2022 and 2021, respectively.

------

**AMEDISYS, INC. AND SUBSIDIARIES**

**SEGMENT INFORMATION**

**(Amounts in millions, except statistical information)**

**(Unaudited)**

***Segment Information - Home Health***

---

| | | |
|:---|:---|:---|
| | **For the Three-Month Periods<br>Ended December 31,** | **For the Three-Month Periods<br>Ended December 31,** |
| | **2022** | **2021** |
| **Financial Information *(in millions)*:** |  |  |
| Medicare | $222.8 | $230.1 |
| Non-Medicare | 119.8 | 107.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net service revenue | 342.6 | 337.3 |
| Cost of service | 195.7 | 193.1 |
| Gross margin | 146.9 | 144.2 |
| Depreciation and amortization | 0.7 | 1.0 |
| Other general and administrative expenses | 89.1 | 84.7 |
| Operating income | $57.1 | $58.5 |
| **Same Store Growth (1):** |  |  |
| Medicare revenue | (6%) | 1% |
| Non-Medicare revenue | 8% | 6% |
| Total admissions | 5% | 2% |
| Total volume (2) | 1% | 2% |
| **Key Statistical Data - Total (3):** |  |  |
| Admissions | 94365 | 87142 |
| Recertifications | 44546 | 46390 |
| Total volume | 138911 | 133532 |
| Medicare completed episodes | 75835 | 78693 |
| Average Medicare revenue per completed episode (4) | $2989 | $2951 |
| Medicare visits per completed episode (5) | 12.5 | 13.7 |
| Visiting clinician cost per visit | $103.83 | $98.16 |
| Clinical manager cost per visit | 11.73 | 10.39 |
| Total cost per visit | $115.56 | $108.55 |
| Visits | 1693215 | 1778512 |

---

------

---

| | | |
|:---|:---|:---|
| | **For the Years Ended <br>December 31,** | **For the Years Ended <br>December 31,** |
| | **2022** | **2021** |
| **Financial Information *(in millions)*:** |  |  |
| Medicare | $891.3 | $914.5 |
| Non-Medicare | 464.2 | 439.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net service revenue | 1355.5 | 1353.8 |
| Other operating income |  | 7.3 |
| Cost of service | 769.0 | 756.6 |
| Gross margin | 586.5 | 604.5 |
| Depreciation and amortization | 4.0 | 4.3 |
| Other general and administrative expenses | 348.5 | 328.5 |
| Operating income | $234.0 | $271.7 |
| **Same Store Growth (1):** |  |  |
| Medicare revenue | (5%) | 8% |
| Non-Medicare revenue | 2% | 9% |
| Total admissions | 3% | 6% |
| Total volume (2) | —% | 5% |
| **Key Statistical Data - Total (3):** |  |  |
| Admissions | 374631 | 353075 |
| Recertifications | 178101 | 183134 |
| Total volume | 552732 | 536209 |
| Medicare completed episodes | 304012 | 311531 |
| Average Medicare revenue per completed episode (4) | $3010 | $2959 |
| Medicare visits per completed episode (5) | 12.9 | 13.9 |
| Visiting clinician cost per visit | $99.90 | $93.44 |
| Clinical manager cost per visit | 11.08 | 9.75 |
| Total cost per visit | $110.98 | $103.19 |
| Visits | 6929137 | 7331935 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Total volume includes all admissions and recertifications.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Total includes acquisitions, start-ups and denovos.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration for the period January 1, 2021 through March 31, 2022 and the reinstatement of sequestration at 1% effective April 1, 2022 and at 2% effective July 1, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.

------

***Segment Information - Hospice***

---

| | | |
|:---|:---|:---|
| | **For the Three-Month Periods<br>Ended December 31,** | **For the Three-Month Periods<br>Ended December 31,** |
| | **2022** | **2021** |
| **Financial Information *(in millions):*** |  |  |
| Medicare | $186.3 | $193.9 |
| Non-Medicare | 11.3 | 11.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net service revenue | 197.6 | 204.9 |
| Cost of service | 103.3 | 110.8 |
| Gross margin | 94.3 | 94.1 |
| Depreciation and amortization | 0.6 | 0.7 |
| Other general and administrative expenses | 51.3 | 54.0 |
| Operating income | $42.4 | $39.4 |
| **Same Store Growth (1):** |  |  |
| Medicare revenue | (4%) | —% |
| Hospice admissions | (8%) | (1%) |
| Average daily census | (2%) | (4%) |
| **Key Statistical Data - Total (2):** |  |  |
| Hospice admissions | 12629 | 13857 |
| Average daily census | 12878 | 13237 |
| Revenue per day, net | $166.82 | $168.24 |
| Cost of service per day | $87.21 | $91.01 |
| Average discharge length of stay | 94 | 90 |

---

---

| | | |
|:---|:---|:---|
| | **For the Years Ended <br>December 31,** | **For the Years Ended <br>December 31,** |
| | **2022** | **2021** |
| **Financial Information *(in millions):*** |  |  |
| Medicare | $744.1 | $750.1 |
| Non-Medicare | 43.7 | 41.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net service revenue | 787.8 | 791.8 |
| Other operating income |  | 6.0 |
| Cost of service | 426.5 | 425.2 |
| Gross margin | 361.3 | 372.6 |
| Depreciation and amortization | 2.3 | 2.7 |
| Other general and administrative expenses | 203.3 | 198.4 |
| Operating income | $155.7 | $171.5 |
| **Same Store Growth (1):** |  |  |
| Medicare revenue | (1%) | —% |
| Hospice admissions | (1%) | 2% |
| Average daily census | (1%) | (4%) |
| **Key Statistical Data - Total (2):** |  |  |
| Hospice admissions | 52656 | 53507 |
| Average daily census | 13091 | 13271 |
| Revenue per day, net | $164.88 | $163.47 |
| Cost of service per day | $89.26 | $87.77 |
| Average discharge length of stay | 91 | 94 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Total includes acquisitions and denovos.

------

***Segment Information - Personal Care***

---

| | | |
|:---|:---|:---|
| | **For the Three-Month Periods<br>Ended December 31,** | **For the Three-Month Periods<br>Ended December 31,** |
| | **2022** | **2021** |
| **Financial Information *(in millions):*** |  |  |
| Medicare | $— | $— |
| Non-Medicare | 15.9 | 15.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net service revenue | 15.9 | 15.1 |
| Cost of service | 12.3 | 11.7 |
| Gross margin | 3.6 | 3.4 |
| Depreciation and amortization |  |  |
| Other general and administrative expenses | 2.3 | 2.4 |
| Operating income | $1.3 | $1.0 |
| **Key Statistical Data - Total:** |  |  |
| Billable hours | 453644 | 500546 |
| Clients served | 7720 | 7867 |
| Shifts | 193220 | 215167 |
| Revenue per hour | $35.07 | $30.09 |
| Revenue per shift | $82.34 | $69.99 |
| Hours per shift | 2.3 | 2.3 |

---

---

| | | |
|:---|:---|:---|
| | **For the Years Ended <br>December 31,** | **For the Years Ended <br>December 31,** |
| | **2022** | **2021** |
| **Financial Information *(in millions):*** |  |  |
| Medicare | $— | $— |
| Non-Medicare | 61.4 | 65.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net service revenue | 61.4 | 65.0 |
| Cost of service | 46.7 | 49.1 |
| Gross margin | 14.7 | 15.9 |
| Depreciation and amortization | 0.1 | 0.2 |
| Other general and administrative expenses | 9.2 | 11.2 |
| Operating income | $5.4 | $4.5 |
| **Key Statistical Data - Total:** |  |  |
| Billable hours | 1851563 | 2275511 |
| Clients served | 10448 | 12074 |
| Shifts | 791596 | 974409 |
| Revenue per hour | $33.15 | $28.54 |
| Revenue per shift | $77.55 | $66.66 |
| Hours per shift | 2.3 | 2.3 |

---

------

***Segment Information - High Acuity Care***

---

| | | |
|:---|:---|:---|
| | **For the Three-Month Periods <br>Ended December 31,** | **For the Three-Month Periods <br>Ended December 31,** |
| | **2022** | **2021** |
| **Financial Information *(in millions):*** |  |  |
| Medicare | $1.9 | $— |
| Non-Medicare | 4.0 | 2.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net service revenue | 5.9 | 2.0 |
| Cost of service | 5.9 | 1.6 |
| Gross margin |  | 0.4 |
| Depreciation and amortization | 0.9 | 0.8 |
| Other general and administrative expenses | 8.3 | 6.1 |
| Operating loss | $(9.2) | $(6.5) |
| **Key Statistical Data - Total:** |  |  |
| Full risk admissions | 108 | 61 |
| Limited risk admissions | 374 | 225 |
| Total admissions | 482 | 286 |
| Full risk revenue per episode | $12282 | $11565 |
| Limited risk revenue per episode | $5545 | $5740 |
| Number of admitting joint ventures (1) | 8 | 7 |

---

---

| | | |
|:---|:---|:---|
| | **For the Years Ended December 31,** | **For the Years Ended December 31,** |
| | **2022** | **2021** |
| **Financial Information *(in millions):*** |  |  |
| Medicare | $5.2 | $— |
| Non-Medicare | 13.3 | 3.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net service revenue | 18.5 | 3.5 |
| Cost of service | 18.2 | 2.5 |
| Gross margin | 0.3 | 1.0 |
| Depreciation and amortization | 3.3 | 1.3 |
| Impairment charge | 3.0 |  |
| Other general and administrative expenses | 33.1 | 10.0 |
| Operating loss | $(39.1) | $(10.3) |
| **Key Statistical Data - Total:** |  |  |
| Full risk admissions | 448 | 107 |
| Limited risk admissions | 1142 | 413 |
| Total admissions | 1590 | 520 |
| Full risk revenue per episode | $11273 | $10457 |
| Limited risk revenue per episode | $5553 | $5693 |
| Number of admitting joint ventures (1) | 8 | 7 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Prior year count has been recast to include admitting joint ventures only.

------

***Segment Information - Corporate***

---

| | | |
|:---|:---|:---|
| | **For the Three-Month Periods<br>Ended December 31,** | **For the Three-Month Periods<br>Ended December 31,** |
| | **2022** | **2021** |
| **Financial Information *(in millions):*** |  |  |
| Other general and administrative expenses | $42.3 | $37.6 |
| Depreciation and amortization | 3.0 | 6.6 |
| Total operating expenses | $45.3 | $44.2 |

---

---

| | | |
|:---|:---|:---|
| | **For the Years Ended <br>December 31,** | **For the Years Ended <br>December 31,** |
| | **2022** | **2021** |
| **Financial Information *(in millions):*** |  |  |
| Other general and administrative expenses | $160.0 | $163.1 |
| Depreciation and amortization | 15.2 | 22.4 |
| Total operating expenses | $175.2 | $185.5 |

---

------

**AMEDISYS, INC. AND SUBSIDIARIES**

**RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES**

**(Amounts in thousands)**

**(Unaudited)**

***Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") Reconciliation:***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month Periods<br>Ended December 31,** | **For the Three-Month Periods<br>Ended December 31,** | **For the Years Ended<br>December 31,** | **For the Years Ended<br>December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Net income attributable to Amedisys, Inc. | $31717 | $34047 | $118609 | $209072 |
| Add: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 9790 | 12873 | 42545 | 70065 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 5711 | 2791 | 22050 | 9476 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5230 | 9138 | 24935 | 30901 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain items (1) | 7441 | 6412 | 58361 | (18028) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest component of certain items (1) |  | (451) | (4445) | (1888) |
| Adjusted EBITDA (2) (7) | $59889 | $64810 | $262055 | $299598 |

---

***Adjusted Net Service Revenue Reconciliation:***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month Periods<br>Ended December 31,** | **For the Three-Month Periods<br>Ended December 31,** | **For the Years Ended<br>December 31,** | **For the Years Ended<br>December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Net service revenue | $562064 | $559317 | $2223199 | $2214112 |
| Add: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain items (1) |  |  | 9305 | (6541) |
| Adjusted net service revenue (3) (7) | $562064 | $559317 | $2232504 | $2207571 |

---

***Adjusted Other Operating Income Reconciliation:***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month Periods<br>Ended December 31,** | **For the Three-Month Periods<br>Ended December 31,** | **For the Years Ended<br>December 31,** | **For the Years Ended<br>December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Other operating income | $— | $— | $— | $13300 |
| Add: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain items (1) |  |  |  | (13300) |
| Adjusted other operating income (4) (7) | $— | $— | $— | $— |

---

***Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month Periods<br>Ended December 31,** | **For the Three-Month Periods<br>Ended December 31,** | **For the Years Ended<br>December 31,** | **For the Years Ended<br>December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Net income attributable to Amedisys, Inc. | $31717 | $34047 | $118609 | $209072 |
| Add: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain items (1) | 6251 | 4764 | 44838 | (12923) |
| Adjusted net income attributable to Amedisys, Inc. (5) (7) | $37968 | $38811 | $163447 | $196149 |

---

------

***Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three-Month Periods<br>Ended December 31,** | **For the Three-Month Periods<br>Ended December 31,** | **For the Years Ended<br>December 31,** | **For the Years Ended<br>December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Net income attributable to Amedisys, Inc. common stockholders per diluted share | $0.97 | $1.04 | $3.63 | $6.34 |
| Add: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain items (1) | 0.19 | 0.15 | 1.37 | (0.39) |
| Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share (6) (7) | $1.16 | $1.18 | $5.01 | $5.95 |

---

(1) The following details the certain items for the three-month periods and years ended December 31, 2022 and 2021:

***Certain Items:***

---

| | | |
|:---|:---|:---|
| | **For the Three-Month Period<br>Ended December 31, 2022** | **For the Year Ended <br>December 31, 2022** |
| | **(Income) Expense** | **(Income) Expense** |
| ***Certain Items Impacting Net Service Revenue:*** | | |
| Contingency accrual | $— | $9305 |
| ***Certain Items Impacting Cost of Service:*** |  |  |
| COVID-19 costs | 1510 | 8747 |
| Clinical optimization and reorganization costs | 33 | 1382 |
| Fuel supplement | 261 | 3576 |
| Integration costs |  | 1712 |
| ***Certain Items Impacting General and Administrative Expenses:*** |  |  |
| Acquisition and integration costs | 1443 | 11298 |
| COVID-19 costs | 107 | 503 |
| Executive Board of Directors transition award |  | 3500 |
| Severance | 993 | 993 |
| Legal fees - non-routine |  | 241 |
| Clinical optimization and reorganization costs | 2247 | 5792 |
| Legal settlement |  | (1058) |
| Fuel supplement | 33 | 251 |
| Investment impairment |  | 3009 |
| ***Certain Items Impacting Total Other Income (Expense):*** |  |  |
| Interest component of certain items |  | 4445 |
| Other (income) expense, net | 814 | 4665 |
| Total | $7441 | $58361 |
| Net of tax | $6251 | $44838 |
| Diluted EPS | $0.19 | $1.37 |

---

------

---

| | | |
|:---|:---|:---|
| | **For the Three-Month Period<br>Ended December 31, 2021** | **For the Year Ended <br>December 31, 2021** |
| | **(Income) Expense** | **(Income) Expense** |
| ***Certain Items Impacting Net Service Revenue:*** | | |
| Contingency accrual | $— | $(6541) |
| ***Certain Items Impacting Other Operating Income:*** |  |  |
| CARES Act funds |  | (13300) |
| ***Certain Items Impacting Cost of Service:*** |  |  |
| COVID-19 costs | 4323 | 20780 |
| ***Certain Items Impacting General and Administrative Expenses:*** |  |  |
| Acquisition and integration costs | 1310 | 7559 |
| COVID-19 costs | 140 | 716 |
| Pre-acquisition legal settlement |  | 1825 |
| ***Certain Items Impacting Total Other Income (Expense):*** |  |  |
| Interest component of certain items | 451 | 1888 |
| Other (income) expense, net | 188 | (30955) |
| Total | $6412 | $(18028) |
| Net of tax | $4764 | $(12923) |
| Diluted EPS | $0.15 | $(0.39) |

---

(2)&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.

(3) Adjusted net service revenue is defined as net service revenue excluding certain items as described in footnote 1.

(4) Adjusted other operating income is defined as other operating income excluding certain items as described in footnote 1.

(5)&nbsp;&nbsp;&nbsp;&nbsp;Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.

(6)&nbsp;&nbsp;&nbsp;&nbsp;Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.

(7)&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA, adjusted net service revenue, adjusted other operating income, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.

## Exhibit 99.2

![](amed4q22ecsupplementalsl001.jpg)

1 Amedisys Fourth Quarter 2022 Earnings Call Supplemental Slides February 16th, 2023 Exhibit 99.2

------

![](amed4q22ecsupplementalsl002.jpg)

2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events. Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website http://www.amedisys.com or by contacting the Amedisys Investor Relations department at (225) 292-2031. We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law. www.amedisys.com NASDAQ: AMED We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business, clinical operations and control processes and SEC filings. FORWARD-LOOKING STATEMENTS Exhibit 99.2

------

![](amed4q22ecsupplementalsl003.jpg)

3 OUR KEY AREAS OF FOCUS Strategic areas of focus and progress made during Q4'22 • Home Health\*: Total same store admissions +5% • Hospice: Total same store admissions -8%, ADC -2% • Personal Care: PC Network drove ~$286K in revenue to Home Health and Hospice via care coordination • High Acuity Care: Admissions +69% over prior year 1 Organic Growth • Quality: Amedisys Apr'23 preview STARS score of 4.49 • 99% of care centers at 4+ Stars based on Apr'23 preview • 46 Amedisys care centers rated at 5 Stars in the Apr'23 preview • Hospice quality – outperforming industry average in all hospice item set (HIS) categories 3 Clinical Initiatives • Focusing on optimizing RN / LPN & PT / PTA staffing ratios. • Current LPN Ratio: 47.7% (vs. 49.0% in 4Q'21) • Current PTA Ratio: 53.9% (vs. 52.9% in 4Q'21) 4 Capacity and Productivity • Acquired Evolution Health on 4/1/22 expanding our footprint in TX, OK and OH (15 care centers) • Acquired 2 care centers from Assisted Care Home Health in North Carolina on 4/1/22 • Entered into 3 new High Acuity Care joint venture partnerships during 2022 5 M&A 2 Recruiting / Retention • Targeting industry leading employee retention amongst all employee categories • Q4'22 Voluntary Turnover 20.7% \*Note: Home Health same store volume is defined as admissions plus recertifications 2022 Reimbursement • Final Home Health industry rule – Amedisys impact +3.2% increase • Final Hospice industry rule – Amedisys impact +2.0% increase (effective 10/1/21) 2023 Reimbursement • Final Hospice industry rule – Amedisys impact +3.8% increase (effective 10/1/22) • Final Home Health industry rule – Amedisys impact flat (effective 1/1/23) 6 Regulatory Exhibit 99.2

------

![](amed4q22ecsupplementalsl004.jpg)

4 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 4Q 2022(1) Home Health total same store admissions +5%; Hospice same store admissions -8%; EBITDA margin decline driven by our acquisitions (additional $4M in losses over Q4'21), the return of sequestration (Q4'21 benefited by $9M), planned wage increases and the shift in Home Health volumes from episodic to per visit payors 1. The financial results for the three-month periods and years ended December 31, 2021 and December 31, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Same Store volume – Includes admissions and recertifications. 3. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. 4. Free cash flow is defined as cash flow from operations less routine capital expenditures and required debt repayments. 5. Medicare sequestration suspended May 1, 2020; reinstated at 2% effective July 1, 2022. Growth Metrics: • Total Admissions: 482 • Number of admitting JVs: 8 Other Statistics: • Patient Satisfaction: 86% High Acuity Care Adjusted Financial Results Growth Metrics: • Billable hours/quarter: -9% • Clients served: -2% Other Statistics: • Revenue per hour: +17% • Cost per hour: +17% Personal Care Same Store Volume (3): • Admissions: -8% • ADC: -2% Other Statistics: • Revenue per Day: $166.82 (-0.8%) • Cost per day: $86.99 (-3.6%) HospiceHome Health Same Store (2)(3) : • Total Admissions: +5% • Total Volume: +1% Other Statistics: • Revenue per Episode(5): $2,989 (+1.3%) • Visiting Clinician Cost per Visit: $102.92 (+6.9%) • Medicare VPE decreased 1.0 (-7.2%) Amedisys Consolidated • Revenue Growth:+0.5% • EBITDA: $60M • EBITDA Margin: 10.7% (ex. Contessa: 12.1%) • EPS: $1.16 (ex. Contessa: $1.36) Amedisys Consolidated Amedisys Consolidated Balance Sheet & Cash Flow • Net debt: $384.3M • Net Leverage ratio: 1.5x • Revolver availability: $520.4M • CFFO: $40.9M • Free cash flow (4): $36.2M • DSO: 46.1 (vs. Q4'21 of 43.2 and down 1.2 days since Q3) $ in Millions, except EPS 4Q21 4Q22 FY 2021 FY 2022 Home Health 337.3$342.6$1,353.8$1,364.8$ Hospice 204.9 197.6 785.3 787.8 Personal Care 15.1 15.9 65.0 61.4 High Acuity Care 2.0 5.9 3.5 18.5 Total Revenue 559.3$562.0$2,207.6$2,232.5$ Gross Margin % 44.1% 43.9% 45.1% 44.2% Adjusted EBITDA 64.8$59.9$299.6$262.1$11.6% 10.7% 13.6% 11.7% Adjusted EPS 1.18$1.16$5.95$5.01$ Free cash flow (4) 1.2$36.2$174.3$114.5$ Exhibit 99.2

------

![](amed4q22ecsupplementalsl005.jpg)

5 65.0% 11.7% 23.3% Home Health Revenue Medicare FFS Private Episodic Per Visit 61.0% 35.2% 2.8% 1.0% Amedisys Consolidated Revenue Home Health Hospice Personal Care High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us for a 30-day period of care, majority of which range from 95% - 100% of Medicare rates • Per Visit: Managed care, Medicaid and private payors who reimburse us per visit performed 94.3% 5.7% Hospice Revenue Medicare FFS Private Hospice Per Day Reimbursement: • Routine Care: Patient at home with symptoms controlled ~97% of the Hospice care AMED provides, in line with overall hospice industry provision of care • Continuous Care: Patient at home with uncontrolled symptoms • Inpatient Care: Patient in facility with uncontrolled symptoms • Respite Care: Patient at facility with symptoms controlled • Home Health: 347 care centers; 34 states & D.C. • Hospice: 164 care centers; 31 states • Personal Care: 13 care centers; 3 states • High Acuity Care: 8 admitting joint ventures; 6 states; 30 referring hospitals • Total AMED: 532 care centers; 37 states and D.C. OUR REVENUE SOURCES: 4Q'22 Exhibit 99.2

------

![](amed4q22ecsupplementalsl006.jpg)

6 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – Q4 2022(1) • Revenue per Episode up 1.3% (primarily due to +3.2% rate increase partially offset by the reinstatement of sequestration at 2% (~$5M)) • Y/Y Total CPV up $7.99 (+7.5%, primarily due to raises, wage inflation, an increase in salaried employees and visit mix) • Cost per episode down 2.0% (Medicare) Home Health Highlights • Net revenue per day -0.8% (+3.8% Hospice rate update effective 10/1/2022 offset by the reinstatement of sequestration at 2% and higher revenue adjustments) • Cost per day down $3.24 (-3.5% primarily due to clinical optimization and reorganization initiatives, lower staffing levels and lower contractor utilization partially offset by planned wage increases and wage inflation) Hospice Highlights 1. The financial results for the three-month periods and years ended December 31, 2021 and December 31, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Pre-Corporate EBITDA does not include any corporate G&A expenses. 3. Same Store information represents the percent change in volume, admissions or ADC for the period as a percent of the volume, admissions or ADC of the prior period. 4. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. 5. Medicare revenue per completed episode reflects the suspension of sequestration for the period May 1, 2020 – March 31, 2022 and the reinstatement of sequestration at 1% on April 1, 2022 and at 2% on July 1, 2022. $ in Millions 4Q21 4Q22 2021 2022 Medicare 230.1$222.8$914.5$900.6$ Non-Medicare 107.2 119.8 439.3 464.2 Home Health Revenue $337.3 $342.6 $1,353.8 $1,364.8 Gross Margin % 43.8% 43.3% 45.1% 44.5% Pre-Corporate EBITDA (2) $63.3 $59.5 $283.0 $260.5 18.8% 17.4% 20.9% 19.1% Operating Statistics Same Store Growth (3)(4) Total admissions 2% 5% 6% 3% Total volume 2% 1% 5% 0% Medicare revenue per episode (5) $2,951 $2,989 $2,959 $3,010 Medicare recert rate 35.1% 33.1% 35.1% 33.7% Total cost per visit $106.67 $114.66 $101.46 $109.41 HOME HEALTH Year Ended $ in Millions 4Q21 4Q22 2021 2022 Medicare 193.9$186.3$743.6$744.1$ Non-Medicare 11.0 11.3 41.7 43.7 Hospice Revenue $204.9 $197.6 $785.3 $787.8 Gross Margin % 46.4% 47.9% 46.9% 46.4% Pre-Corporate EBITDA (2) $41.4 $44.4 $171.6 $166.3 20.2% 22.4% 21.9% 21.1% Operating Statistics Admit growth - same store (3)(4) -1% -8% 2% -1% ADC growth - same store (3)(4) -4% -2% -4% -1% ADC 13,237 12,878 13,271 13,091 Avg. discharge length of stay 90 94 94 91 Revenue per day (net) $168.24 $166.82 $162.12 $164.88 Cost per day $90.23 $86.99 $86.15 $88.32 HOSPICE Year Ended Exhibit 99.2

------

![](amed4q22ecsupplementalsl007.jpg)

7 4Q21 1Q22 2Q22 3Q22 4Q22 Salary and Benefits 21.7 23.8 23.3 22.1 24.0 Other 10.4 10.2 6.7 12.2 11.7 Corp. G&A Subtotal 32.1 34.0 30.1 34.3 35.7 Non-cash comp 4.0 1.6 2.6 1.2 2.3 Adjusted Corporate G&A 36.1 35.6 32.7 35.5 38.0 $ in Millions 4Q21 1Q22 2Q22 3Q22 4Q22 Home Health Segment - Total 84.7 83.2 87.8 86.9 89.0 % of HH Revenue 25.1% 24.8% 25.2% 25.7% 26.0% Hospice Segment - Total 54.0 51.3 50.8 48.6 50.8 % of HSP Revenue 26.4% 26.6% 25.6% 24.4% 25.7% Personal Care Segment - Total 2.4 2.2 2.3 2.3 2.4 % of PC Revenue 15.7% 15.8% 15.2% 14.0% 14.9% High Acuity Care Segment - Total 6.2 7.1 8.8 8.8 8.4 % of HAC Revenue 305.7% 256.9% 199.8% 160.7% 144.2% Total Corporate Expenses 36.1 35.6 32.7 35.5 38.0 % of Total Revenue 6.5% 6.5% 5.8% 6.4% 6.8% Total 183.4 179.4 182.4 182.1 188.6 % of Total Revenue 32.8% 32.9% 32.2% 32.6% 33.6% GENERAL & ADMINISTRATIVE EXPENSES – ADJUSTED (1,2) Notes: • Year over year total G&A as a percentage of revenue increased 80 basis points ($5 million); excluding Contessa ($2 million) and home health acquisitions ($3 million), total G&A is flat versus prior year (G&A as a % of revenue excluding Contessa and home health acquisitions = 32.4%) • Planned wage increases and higher information technology fees and facilities-related costs were offset by savings associated with clinical optimization and reorganization initiatives and reductions in staffing levels • Total G&A increased $8 million sequentially excluding Contessa and our home health acquisitions due to higher incentive compensation costs, lower gains on the sale of fleet vehicles and a seasonality driven increase in health insurance 1. The financial results for the three-month periods ended December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Adjusted G&A expenses do not include depreciation and amortization. Impacted by acquisitions, raises and the addition of resources to support growth 32.8% 32.9% 32.2% 32.6% 33.6% 31.7% 31.6% 30.7% 31.3% 32.4% 29.0% 31.0% 33.0% 35.0% 4Q21 1Q22 2Q22 3Q22 4Q22 Total G&A as a Percent of Revenue G&A as a Percent of Revenue Ex-Contessa Exhibit 99.2

------

![](amed4q22ecsupplementalsl008.jpg)

8 OPERATIONAL EXCELLENCE: HOME HEALTH COST PER VISIT (CPV)-ADJUSTED YOY Total CPV impacted by labor cost pressures and lower visits \*Note: Direct comparison with industry competitors CPV calculation $25.00 $50.00 $75.00 $100.00 4Q21 3Q22 4Q22 Cost Per Visit (CPV) Salaries Contractors Benefits Transportation $96.28 $99.43 $102.92 Components 4Q'21 3Q'22 4Q'22 YoY Variance Detail Initiatives Salaries $69.73 $72.08 $73.94 $4.21 YoY increase due to visit mix, planned wage increases, wage inflation and an increase in salaried employees Sequential increase due to higher new hire pay, visit mix and one additional month of raises Staffing mix optimization, productivity and scheduling improvement initiatives in place to help overcome salary increases Contractors $4.93 $5.21 $5.61 $0.68 YoY variance due to an increase in rates (utilization flat) Sequential variance due to increased utilization Focused efforts on filling positions with full-time clinicians Benefits $14.52 $14.35 $15.66 $1.14 YoY and Sequential variances due to higher payroll taxes on salary increases and an increase in health insurance costs due to the seasonality of claims Focus on cost containment and spend optimization with specific focus on high-cost claims Transportation & Supplies $7.10 $7.79 $7.71 $0.61 YoY variance due to higher fleet fuel costs, mileage reimbursement and rate increases for freight and certain supplies \*Visiting Clinician CPV $96.28 $99.43 $102.92 $6.64 Clinical Managers $10.39 $11.33 $11.74 $1.35 Fixed cost associated with non-visiting clinicians YoY increase driven by additional staff, planned wage increases and impact of fixed costs on lower visit volumes Unit cost reduced as volume increases Total CPV $106.67 $110.76 $114.66 $7.99 Exhibit 99.2

------

![](amed4q22ecsupplementalsl009.jpg)

9 DRIVING TOP LINE GROWTH Home Health admissions growth remains strong; volume impacted by mix shift. Sequential average daily census decline due to softer admission volumes and seasonality. 2% 0% -2% 1% 1% 2% 2% 0% 5% 5% -4.0% -2.0% 0.0% 2.0% 4.0% 6.0% 50,000 100,000 150,000 4Q21 1Q22 2Q22 3Q22 4Q22 Volume SS Volume Growth SS Admit Growth Home Health Growth Hospice Growth Personal Care Total Hours / Quarter 0 200,000 400,000 600,000 4Q21 1Q22 2Q22 3Q22 4Q22 Billable Hours -4% -3% 0% 1% -2% -1% 2% 6% -3% -8% -9.0% -6.0% -3.0% 0.0% 3.0% 6.0% 12,000 12,500 13,000 13,500 14,000 4Q21 1Q22 2Q22 3Q22 4Q22 ADC Admits SS ADC Growth SS Admit Growth Exhibit 99.2

------

![](amed4q22ecsupplementalsl010.jpg)

10 INDUSTRY LEADING QUALITY SCORES Quality of Patient Care (QPC) Patient Satisfaction (PS) • Amedisys maintains a 4-Star average in the Apr 2023 HHC Preview with 99% of our providers (representing 99% of care centers) at 4+ Stars and 82% of our providers (representing 83% of care centers) at 4.5+ Stars. •31 Amedisys providers (representing 46 care centers) rated at 5 Stars. Notes: (1) CMS did not provide QPC Star and HH-CAHPS performance releases in 2021 due to COVID-19 PHE. (2) Apr 2023 QPC Star Preview performance period = Jul 2021 – Jun 2022 (Jul 2020 - Jun 2021 for ACH). (3) Jan 2023 HH-CAHPS Preview performance period = Jul 2021 – Jun 2022 (4) QPC Star and HH-CAHPS Results for Amedisys Legacy providers only. Metric Jul 22 Release Oct 22 Release Jan 23 Release Apr 23 Preview Quality of Patient Care 4.46 4.49 4.49 4.49 Entities at 4+ Stars 99% 100% 99% 99% 3.00 3.50 4.00 4.50 QPC Industry Performance Amedisys QPC Industry Avg QPC Top Competitor CMS Blind Period Metric Apr 22 Release Jul 22 Release Oct 22 Release Jan 23 Release Patient Satisfaction Star 3.73 3.92 3.60 3.57 Performance Over Industry +3% +5% +3% +1% 3.00 3.50 4.00 4.50 PS Industry Performance Amedisys PS Score PS Industry Avg PS Top Competitor CMS Blind Period Exhibit 99.2

------

![](amed4q22ecsupplementalsl011.jpg)

11 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers. Exhibit 99.2

------

![](amed4q22ecsupplementalsl012.jpg)

12 DEBT AND LIQUIDITY METRICS Net leverage ~1.5x 1. Net debt defined as total debt outstanding ($438.4M) less cash ($54.1M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($262.1M). 3. Liquidity defined as the sum of cash balance and available revolving line of credit. Outstanding Revolver - Outstanding Term Loan 435.9 Promissory Notes 0.2 Finance Leases 2.3 Total Debt Outstanding 438.4 Less: Deferred Debt Issuance Costs (3.5) Total Debt - Balance Sheet 434.9 Total Debt Outstanding 438.4 Less Cash (54.1) Net Debt (1) 384.3 Leverage Ratio (net) (2) 1.5 Term Loan 450.0 Revolver Size 550.0 Borrowing Capacity 1,000.0 Revolver Size 550.0 Outstanding Revolver - Letters of Credit (29.6) Available Revolver 520.4 Plus Cash 54.1 Total Liquidity (3) 574.5 As of: 12/31/22 Credit Facility Outstanding Debt As of: 12/31/22 Exhibit 99.2

------

![](amed4q22ecsupplementalsl013.jpg)

13 CASH FLOW STATEMENT HIGHLIGHTS (1) Total cash flow from operations for 2022 of $133M. Results impacted by repayment of deferred payroll taxes ($27M) in Q4-22 and ZPIC audit repayment ($38M). 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments. $ in Millions 4Q21 1Q22 2Q22 3Q22 4Q22 GAAP Net Income 34.0 31 .7 29.0 25.4 31 .5 Changes in working capital (27 .1) (5.4) 1 3 .6 (67 .3) 6.9 Depreciation and amortization 9.1 8.0 6.2 5.5 5.2 Non-cash compensation 5.9 7 .3 5.1 3 .5 0.6 Deferred income taxes 9.9 3 .2 2.8 1 3 .0 4.3 Other (26.6) 3 .8 0.7 6.3 (7 .6) Cash flow from operations 5.2 48.6 57.4 (13.6) 40.9 Capital expenditures - routine (0.7) (0.9) (1 .5) (1 .5) (1 .5) Required debt repay ments (3.3) (3 .8) (3.2) (3 .2) (3 .2) Free cash flow 1.2 43.9 52.7 (18.3) 36.2 Capital Deployment Acquisitions (5.1) - (7 3.3) 1 .4 - Share Repurchases (1 5.0) - (1 7 .4) - - Total (20.1) - (90.7) 1.4 - Exhibit 99.2

------

![](amed4q22ecsupplementalsl014.jpg)

14 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Q4 adjustments primarily related to clinical optimization and reorganization initiatives, COVID-19 costs, acquisition and integration costs and severance. $000s Income Statement Line Item 4Q21 1Q22 2Q22 3Q22 4Q22 Revenue Contingency accrual Net Serv ice Rev enue -$-$8,37 4$931$-$ Cost of Service Clinical optimization and reorganization costs Cost of Serv ice, Excluding Depreciation & Amortization - - 1 95 1 ,1 54 33 COVID-1 9 costs Cost of Serv ice, Excluding Depreciation & Amortization 4,323 3,7 33 1 ,803 1 ,7 01 1 ,51 0 Integration costs Cost of Serv ice, Excluding Depreciation & Amortization - - 1 ,401 31 1 - Fuel supplement Cost of Serv ice, Excluding Depreciation & Amortization - 337 1 ,01 6 1 ,962 261 G&A Acquisition and integration costs G&A, Salaries and benefits 41 9 31 6 1 ,67 4 1 ,025 37 8 Clinical optimization and reorganization costs G&A, Salaries and benefits - - 81 0 1 ,386 (1 52) COVID-1 9 costs G&A, Salaries and benefits 9 24 1 2 - 3 Executiv e Board of Directors transition award G&A, Salaries and benefits - 3 ,500 - - - Sev erance G&A, Salaries and benefits - - - - 993 Fuel supplement G&A, Salaries and benefits - - - 21 8 33 Acquisition and integration costs G&A, Other 891 1 ,062 3,649 2,1 29 1 ,065 Legal fees - non-routine G&A, Other - 51 1 90 - - COVID-1 9 costs G&A, Other 1 31 1 29 7 2 1 59 1 04 Clinical optimization and reorganization costs G&A, Other - - 59 1 ,290 2,399 Legal settlement G&A, Other - - (1 ,058) - - Other Items Inv estment impairment Inv estment impairment - - - 3 ,009 - Interest component of certain items Interest Expense 451 - 4,652 (207) - Other (income) expense, net Total Other (Expense) Income, Net 1 88 2 ,298 7 60 7 93 81 4 Total 6,412$11,450$23,609$15,861$7 ,441$ EPS Impact 0.15$0.26$0.56$0.36$0.19$ EBITDA Impact 5,961$11,450$18,957$16,068$7 ,441$ Exhibit 99.2

------

![](amed4q22ecsupplementalsl015.jpg)

15 2023 Guidance Exhibit 99.2

------

![](amed4q22ecsupplementalsl016.jpg)

16 AMEDISYS 2023 PRELIMINARY GUIDANCE Revenue, EBITDA and EPS guidance ranges for FY 2023 ($M except for EPS) Total AMED Adjusted Revenue $2,244 - $2,274 Adjusted EBITDA $230 - $240 Adjusted EPS $4.13 - $4.36 Exhibit 99.2

------

![](amed4q22ecsupplementalsl017.jpg)

17 2022 – 2023 EBITDA WATERFALL Category Description Reimbursement, Net Home Health rate update: 0%, Hospice rate update: +3.8% Sequestration Headwind of $13M from 2022 to 2023 Compensation & Benefits Impact of 2022 raises (Aug 2022) plus 4% for 2023 raises and wage inflation; Benefits increase reflects investments focused on improving medical plans and family support: higher HSA contributions, enhanced disability coverage, paid paternal bonding leave and family caregiving leave STI / LTI 2022 payout of 10% for corporate plan vs. 100% for 2023; lower payouts in 2022 for all other incentive compensation plans based on 2022 performance COVID Costs No longer adding back COVID costs in 2023 - $6M headwind into 2023 Mix Shift Continued shift in Home Health payor mix from episodic volumes which generate higher revenue to non-episodic volumes Revenue Growth & Margin Improvement Home Health total volume growth +5%; Hospice average daily census growth +3%; continued improvement in clinician utilization Other Items Medical supply and freight cost increases, non-recurring favorable legal settlement in 2022 Clinical Optimization & Reorganization Initiatives Savings related to clinical optimization and reorganization initiatives Investments Denovos, Medalogix, workforce optimization and automation $187 $235 $262 $26 $13 $45 $23 $6 $14 $52 $17 $2 $7 $8 $4 2022 EBITDA Reimbursement, Net Sequestration Compensation & Benefits STI/LTI COVID Costs Mix Shift Revenue Growth & Margin Improvement Clinical Optimization & Reorganization Initiatives Mileage Reimbursement Investments Other Items Divestiture of PCL 2023 EBITDA Adjusted EBITDA Waterfall ($M) Exhibit 99.2

------

![](amed4q22ecsupplementalsl018.jpg)

18 2023 Guidance Considerations Amedisys Consolidated • Tax rate ~27% • Cash tax rate ~19% • Diluted share count ~32.9 million shares • Capital Expenditures ~$13- $15 million • Salary increases and wage inflation ~4% • Benefits increase (including enhancements to medical and disability plans and new family support programs) ~7% (4% pricing/claims costs, 3% growth/headcount) • Incentive compensation increase ~ $23 million • Excludes future acquisitions, related integration costs and potential share repurchase Home Health Personal CareHospice • Total same store admission growth: ~5% • Flat pricing • Expiration of sequestration relief -$7 million • Continued shift in payor mix from episodic to per visit -$14 million • Clinical optimization and reorganization initiatives +$7 million • Continued focus on Quality of Care (Stars and Acute Care Hospitalization rates) • Total same store admission growth: ~2% • +3.8% rate increase • Expiration of sequestration relief -$6 million • Clinical optimization and reorganization initiatives +$10 million • On February 10, 2023, entered into a definitive agreement to sell our Personal Care line of business • Divestiture expected to close during Q2-2023 EBITDA impacted by expiration of sequestration relief, COVID-19 costs (no longer classified as an adjusting item) and higher compensation, benefits and incentive compensation costs 2023 Investments • Total Investments in business of ~$8M • Innovations & Projects ($6M) – spend related to automation, workforce optimization and expansion of Medalogix products • Denovos ($1M) – Expansion of denovo program • High Acuity Revenue: $27M - $47M • Awarded BlueCross BlueShield of TN palliative care contract High Acuity Care Exhibit 99.2

------

![](amed4q22ecsupplementalsl019.jpg)

19 2023 HIGH ACUITY SEGMENT REVENUE ($ in millions) 2023A to 2023P Revenue Bridge 2022 → 2023 Revenue Growth: 3.9x $47 2023 Revenue Composition by Clinical Program (1) Excludes $6M of 2022 revenue to be reported in Home Health segment in 2023 (2) $47M represents the high end of the $27M - $47M range $10 $7 $8 $22 Hospital at Home (full risk episodes) SNF at Home (full risk episodes) Completing Hospital at Home (limited risk episodes) Palliative Care at Home (varied risk arrangements) Exhibit 99.2

------

![](amed4q22ecsupplementalsl020.jpg)

20 Environmental, Social, Governance (E.S.G.) Considerations Exhibit 99.2

------

![](amed4q22ecsupplementalsl021.jpg)

21 ENVIRONMENTAL, SOCIAL, GOVERNANCE (E.S.G.) CONSIDERATIONS Sustainable, high-quality, patient focused, home-based care model Environmental • Amedisys is dedicated to the sustainability of our business and the communities in which we serve • Environmental health has a strong correlation with physical health • A greener fleet – newer vehicles, in circulation for a shorter time, optimize fuel usage. Sophisticated scheduling practices reduce our clinicians' driving time and fuel usage helping to minimize our carbon footprint • Virtual care centers, along with flexible working schedules and locations, have created fewer emissions Social • Amedisys strives to create an organizational culture and climate in which every individual is valued, all team members have a sense of belonging with one another and to the organization and feel empowered to do their best work • Provider of Home Health and Hospice services to frail, elderly patients in their most preferred care location – their homes • Highest quality Home Health company as measured by Quality of Patient Care Star scores (4.49 Stars) • The Amedisys Foundation was formed to provide support to our patients and employees. The Amedisys Foundation has two funds: the Patients' Special Needs Fund and the Amedisys Employees 1st Fund. The Patients' Special Needs Fund provides financial assistance to our home health, hospice, personal care and high acuity care patients during a difficult time Governance • Amedisys has a culture of compliance starting with oversight from the Board of Directors and cascading down to the care center level • Our Board of Directors operates several sub-committees including: • Quality of Care Committee • Compliance & Ethics Committee • Audit Committee • Compensation Committee • Nominating & Corporate Governance Committee • Nominating and Corporate Governance Committee oversees our strategy on corporate social responsibility, including evaluating the impact of Company practices on communities and individuals, and develops and recommends to our Board of Directors for approval matters relating to the Company's corporate social responsibility and ESG considerations Exhibit 99.2

------

## Exhibit 99.3

**Exhibit 99.3**

![draftof8k050418image1a.gif](draftof8k050418image1a.gif)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Amedisys Announces Divestiture of its Personal Care Division**

*Amedisys and HouseWorks form Care Coordination Partnership to Enhance Amedisys Personal Care Network*

BATON ROUGE, LA., February 15, 2023 -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care, today announces that it has signed a definitive agreement to divest its Personal Care division to HouseWorks, LLC, a leading provider of personal care services in Massachusetts, New Hampshire, Maine and Pennsylvania.

HouseWorks, in partnership with eCaring, will join the Amedisys personal care network and form a care coordination partnership to deliver comprehensive, seamless care to the communities both organizations jointly serve. In addition to the HouseWorks footprint, eCaring provides mission critical software and services to over 75 home care agencies with 15,000 + caregivers, delivering care to more than 35,000 seniors each year. By establishing this network partnership, Amedisys retains and expands access to personal care services to support its patients in the current and growing footprints served by HouseWorks and eCaring.

"Our Personal Care division was started with the sole mission to provide patients with a true continuum of care in the home," stated Amedisys Chairman and Chief Executive Officer Paul Kusserow. "We strongly believe in the value of personal care and this divestiture allows our personal care division to grow under a proven leader in the industry while Amedisys focuses our attention on our core business units of Home Health, Hospice and High Acuity Care. We're excited to strengthen the development of our network with HouseWorks and eCaring. Through Contessa, we have developed more experience and capabilities of connecting a network of providers to deliver care in risk-based models. Our personal care network strategy is another tool for us to continue to lead innovative care delivery where patients prefer to be – in their homes."

Amedisys acquired its first personal care company, Associated Home Care (AHC) based in Massachusetts, in 2016. Mike Trigilio, CEO of HouseWorks, was the CEO of AHC prior to its sale to Amedisys and joined the Amedisys leadership team as the President of the Personal Care division prior to his departure in March 2020.

"The sale of AHC and my time with Amedisys were among the best years in my long career in personal care services," remarked HouseWorks Chief Executive Officer Mike Trigilio. "Many of the innovations that we are implementing today at HouseWorks were forged in partnership with the Amedisys team. It is an honor to rejoin many of my former colleagues, to welcome the employees, caregivers and clients of the Amedisys Personal Care division to the HouseWorks family, and to have the opportunity to collaborate with Amedisys going forward across the entire continuum of care."

The transaction is expected to close in the second quarter of 2023.

**About Amedisys:**

Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; inpatient hospital, palliative, and skilled nursing facility ("SNF") care in their homes; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 102,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 20,000 employees, in 532 care centers in 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 465,000 patients and clients in need every year, performing more than 11.2 million visits annually. For more information about the Company, please visit: www.amedisys.com.

------

**About HouseWorks**:

For more than 20 years, HouseWorks has provided older adults and their families the highest standard of private, dependable in-home care. Our proprietary BetterCare at Home® approach leverages personalized care services and innovative technology to guide the work of our caregivers as we help seniors stay safe, comfortable, and engaged in their life – at home. HouseWorks is a national and local leader in home care serving Massachusetts, New Hampshire, Pennsylvania, and Maine.

**About eCaring:**

eCaring offers home care agencies a software solution for scheduling, delivering, and billing home care services. eCaring also offers mobile applications to support the delivery of home care services, electronic visit verification (EVV), and secure communications for nurses and caregivers. eCaring is a complete home care solution focused on gathering information from the home and turning this information into action to improve outcomes and reduce costs.

**Amedisys Forward-Looking Statements:** 

When included in this press release, words like "believes," "belief," "expects," "strategy," "plans," "anticipates," "intends," "projects," "estimates," "may," "might," "could," "would," "should" and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors or payment methodologies; changes in the case mix of our patients; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

**Contact:&nbsp;&nbsp;&nbsp;&nbsp;**

Nick Muscato&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kendra Kimmons

Amedisys, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amedisys, Inc.

Investor Relations&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Media Relations

615.928.5452&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;225.299.3720

<u>nick.muscato@amedisys.com</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>kendra.kimmons@amedisys.com</u>

## Exhibit 99.4

**Exhibit 99.4**

![draftof8k050418image1b.gif](draftof8k050418image1b.gif)

**Amedisys Partners with BlueCross BlueShield of Tennessee to Provide** 

**Palliative Care at Home to Members** 

*Program focuses on enhancing quality of life for members in Middle Tennessee in their homes* 

**Nashville, Tenn. – February 15, 2023** – Today, Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care, announced a new agreement with BlueCross BlueShield of Tennessee to provide members in Middle Tennessee with palliative care in the comfort of their homes.

Palliative care is specialized medical care for people living with complex, chronic or advanced stage illness, such as cancer or heart failure. Patients in palliative care receive ongoing home-based treatment and care coordination that aims to enhance quality of life and manage symptoms.

"BlueCross BlueShield of Tennessee has shown they are committed to making healthcare more affordable and more convenient for its members, in their homes," said Paul Kusserow, Chairman and Chief Executive Officer at Amedisys. "As one of our first arrangements of this kind, it accelerates Amedisys' strategic goal of moving to mutually beneficial, risk-based models with payors. We are proud to work with innovative companies like BlueCross BlueShield of Tennessee to offer high-acuity care in the home."

With this program, BlueCross BlueShield of Tennessee's members can receive palliative care in-person or via telehealth from Amedisys' clinicians including doctors, nurse practitioners and nurses at no additional cost. Eligible members will receive information from Amedisys on the program and how to enroll in the coming weeks.

"Palliative Care at Home brings coordinated and specialized care into the homes of our members and avoids unnecessary hospitalization," said Dr. Angeline Brunetto, Vice President and Chief Medical Officer of BlueCross BlueShield of Tennessee's senior care division. "We believe in the benefit of offering high quality care where our members are most comfortable - their home. Increasingly, this is what patients want and we are proud to offer these services to our Middle Tennessee members."

For more information on the Palliative Care at Home program, please visit https://www.amedisys.com/services/palliative-care/

**About Amedisys**

Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; inpatient hospital, palliative, and skilled nursing facility ("SNF") care in their homes; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 102,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 20,000 employees, in 532 care centers in 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 465,000 patients and clients in need every year, performing more than 11.2 million visits annually. For more information about the Company, please visit: www.amedisys.com.

------

**About BlueCross BlueShield of Tennessee** 

BlueCross BlueShield of Tennessee is a taxpaying, not-for-profit health plan serving more than 3.3 million members in Tennessee and around the country. The Chattanooga-based company was founded in 1945 and has brought peace of mind to its members and local communities for more than 75 years. BlueCross BlueShield of Tennessee Inc. is an independent licensee of the BlueCross BlueShield Association. For more information, visit the company's news center at bcbstnews.com.

**Amedisys Forward-Looking Statements:** When included in this press release, words like "believes," "belief," "expects," "strategy," "plans," "anticipates," "intends," "projects," "estimates," "may," "might," "could," "would," "should" and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors or payment methodologies; changes in the case mix of our patients; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

**Contact:**

Nick Muscato&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kendra Kimmons

Amedisys, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amedisys, Inc.

Investor Relations&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Media Relations

615.928.5452&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;225.299.3720

<u>nick.muscato@amedisys.com</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>kendra.kimmons@amedisys.com</u>

&nbsp;&nbsp;&nbsp;&nbsp;

<br>